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Abstract
Polyclonal B cell activation might be related to pathogenic over-
expression of B-cell-activating factor (BAFF) in primary
Sjögren's syndrome (pSS) and other autoimmune diseases. We
therefore investigated whether BAFF over-expression in pSS
could be a primary, genetically determined event that leads to
the disease. The complete BAFF gene was sequenced in
Caucasian pSS patients and control individuals. The only single
nucleotide polymorphism frequently observed, namely -871 T/C
in the promoter region, was then genotyped in 162 French
patients with pSS and 90 French control individuals. No
significant differences in allele (T allele frequency: 49.7% in
patients with pSS versus 50% in controls; P  = 0.94) and
genotype frequencies of BAFF polymorphism were detected
between pSS patients and control individuals. BAFF gene
polymorphism was not associated with a specific pattern of
antibody secretion either. T allele carriers had significantly
increased BAFF protein serum levels (mean values of 8.6 and
5.7 ng/ml in patients with TT and TC genotypes, respectively,
versus 3.3 ng/ml in patients with CC genotype; P  = 0.01),
although no correlation was observed between BAFF
polymorphism and mRNA level. In conclusion, BAFF gene
polymorphism is neither involved in genetic predisposition to
pSS nor associated with a specific pattern of antibody
production.
Introduction
Polyclonal B-cell activation might be related to pathogenic
over-expression of B-cell-activating factor (BAFF; also known
as TNFSF13B, BLyS, THANK and TALL-1) in primary Sjö-
gren's syndrome (pSS) and other autoimmune diseases [1]. In
pSS, an increase in serum BAFF level was reported in all pub-
lished surveys of patients with pSS [2-5]. In addition, we and
others [4-6] have demonstrated increased BAFF expression in
salivary glands, the main target of this autoimmune disease.
We hypothesized that BAFF over-expression in pSS could be
a primary, genetically determined event that leads to the dis-
ease. We therefore investigated the genetic association
between BAFF polymorphisms and pSS.
Materials and methods
Because BAFF polymorphisms have never been studied in
Caucasian patients, the complete BAFF gene was sequenced
in 13 patients with pSS and 13 healthy control individuals.
Two single nucleotide polymorphisms (SNPs) were detected
in the promoter region of the BAFF gene: -661 A/G, a rare var-
BAFF = B-cell-activating factor; CI = confidence interval; PBMC = peripheral blood mononuclear cell; pSS = primary Sjögren's syndrome; RA = 
rheumatoid arthritis; RT-PCR = reverse transcriptase polymerase chain reaction; SLE = systemic lupus erythematosus; SNP = single nucleotide pol-
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iation observed in only one healthy individual; and -871 T/C,
which was observed among patients with pSS with a C allele
frequency of 46%. Five other SNPs, previously reported in
Japanese patients with rheumatoid arthritis (RA) and systemic
lupus erythematosus (SLE) [7], were not detected in the
present study of Caucasian patients. After isolation of
genomic DNA from peripheral blood mononuclear cells
(PBMCs), the -871 T/C SNP was genotyped using PCR
restriction fragment length polymorphism method in 162 unre-
lated French patients with pSS (110 patients with anti-SSA
and/or anti-SSB autoantibodies and 52 patients without
autoantibodies). Patients were defined in accordance with
European–American consensus group criteria and were
recruited from the Departments of Rheumatology of Bicêtre
and Strasbourg Hospitals. Ninety healthy French blood donors
were genotyped as controls. All patients and control individu-
als were Caucasians. The characteristics of the patients are
summarized in Table 1. The patients were receiving no immu-
nosuppressive medications other than corticosteroids (daily
dose of ≤10 mg of prednisone; n = 14) or hydroxychloroquine
(n = 13). Of the 162 patients, 95 were included in a previous
study in which BAFF level was reported [8]. The methods of
assessment of serum BAFF using enzyme-linked immunosorb-
ent assay were previously reported [2].
Levels of BAFF mRNA were determined by real-time quantita-
tive PCR using a LightCycler (Roche Diagnostics, Manheim,
Germany). PBMCs were isolated from 20 ml venous blood
samples from 40 patients with pSS and stored at -70°C in
RNAlater (Qiagen, Valencia, CA). Total RNA was extracted
from PBMCs using RNeasy Mini Kit (Qiagen). The cDNA syn-
thesis was performed using Enhanced Avian HS RT-PCR
(Sigma-Aldrich, Saint Quentin Fallavier, France). BAFF and β-
actin mRNA levels were assessed by real-time quantitative
PCR using the following primers: 5'-TGAAACACCAACTATA-
CAAAAAG-3' and 5'-TCAATTCATCCCCAAAGACAT-3' for
BAFF; and 5'-GCTGTGCTACGTCGCCCT-3' and 5'-AAGG-
TAGTTTCGTGGATGCC-3' for β-actin. Primers were
designed to be specific for full-length BAFF, excluding any
amplification of ∆BAFF. Each sample was run with initial incu-
bation at 96°C for 10 minutes, and thermal conditions fol-
lowed 40 cycles at 95°C for 10 s, 60°C for 15 s and 72°C for
20 s. For each run, serially diluted cDNA of K562 cells was
used as a quantitative standard. To correct for variations in
mRNA recovery and the reverse transcription yield, the
amounts of BAFF cDNA were normalized to β-actin.
Genotypic and allelic frequencies were compared by χ2 test-
ing. The association between BAFF polymorphism and BAFF
protein or mRNA level was analyzed using the Mann–Whitney
U test. The association between BAFF polymorphism and
serum gammaglobulin, IgG, and rheumatoid factor levels was
analyzed using analysis of variance. Statistical analysis was
performed using Analyse-it for Microsoft Excel (Leeds, Eng-
land, UK).
Results
The allelic and genotypic distribution of -871 T/C polymor-
phism were in Hardy–Weinberg equilibrium. No significant dif-
ferences in allele and genotype frequencies of BAFF
polymorphism were detected between patients with pSS and
control individuals (T allele frequency: 49.7% in patients with
pSS versus 50% in controls, P = 0.94; TT genotype: 26% in
pSS versus 23.3%; TC genotype: 48.5% versus 53.4%, CC
genotype: 25.5% versus 23.3%, P = 0.78). No significant dif-
ference was observed in terms of clinical presentation (36 and
38% of extraglandular involvement in T and C allele carriers,
respectively; P = 0.8). BAFF polymorphism was not involved
in genetic predisposition to a specific pattern of autoantibody
secretion either (T allele frequency in patients without autoan-
tibody: 45%; in patients positive for anti-SSA autoantibody
only: 48%; in patients positive for anti-SSA + anti-SSB
autoantibody: 52%; P = 0.76). No association was observed
between BAFF gene polymorphism and mean serum gamma-
globulin, IgG, or rheumatoid factor levels assessed by neph-
elometry (gammaglobulin, IgG, and rheumatoid factor,
respectively: 11.9 ± 0.7 g/l, 13.8 ± 1.1 g/l and 154.2 ± 75.2
IU/l in patients with CC genotype [P = 0.3]; 14.1 ± 1 g/l, 15.7
± 1.2 g/l and 157.8 ± 32.4 IU/l in patients with TC genotype
[P = 0.61]; and 12.7 ± 1 g/l, 14.9 ± 1.3 g/l, 267.7 ± 113.5
IU/l in patients with TT genotype [P = 0.43]).
A significant association was observed between -871 T/C pol-
ymorphism and serum BAFF level: T allele carriers had a sig-
nificantly higher BAFF level than did C allele carriers. Thus,
mean BAFF levels were 8.6 ± 2 and 5.7 ± 0.6 ng/ml in
patients with TT and TC genotypes versus 3.3 ± 0.4 ng/ml in
patients with CC genotype (P = 0.01; Fig. 1). T allele was
associated with increased BAFF levels in the 27 patients with-
out autoantibodies (CC genotype [n = 7]: 2.5 ± 0.6 ng/ml; TC
genotype [n = 13]: 4.5 ± 0.7 ng/ml; TT genotype [n = 7]: 11.6
Table 1
Characteristics of the population studied
Characteristic Value
Age (mean ± SD) 57.3 ± 12.1
Women/men (n)1 5 6 / 6
No anti-SSA or anti-SSB autoantibodies (n [%]) 52 (32)
Anti-SSA autoantibody only (n [%]) 54 (33.4)
Anti-SSA and anti-SSB autoantibodies (n [%]) 56 (34.6)
Positive rheumatoid factor finding (n [%]) 89 (55)
Rheumatoid factor level (IU/l; mean ± SD) 183.6 ± 365
Serum IgG level (g/l; mean ± SD) 15 ± 7.2
Focus score ≥1 on labial salivary gland (n = 145; n 
[%])
130 (90)
SD, standard deviation.Available online http://arthritis-research.com/content/8/1/R30
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± 6.3 ng/ml; P = 0.08) and in the 68 patients with anti-SSA or
anti-SSB antibodies (CC genotype [n = 16]: 3.6 ± 0.6 ng/ml;
TC genotype [n = 31]: 6.1 ± 0.8 ng/ml; TT genotype [n = 21]:
7.1 ± 1.7 ng/ml; P = 0.05; Fig. 2). Serum BAFF level did not
differ significantly according to the presence of concomitant
treatment with low-dose corticosteroids (n = 14 [daily dose
≤10 mg in all patients]; median BAFF level: 4.3 ng/ml [95%
confidence interval (CI) 2.7–6.5] versus 5.3 ng/ml [95% CI
2.9–15.6] in patients without corticosteroids; P = 0.76) or
with hydroxychloroquine (n = 13; median BAFF level: 3.8 ng/
ml [95% CI 1.7–8.7] versus 4.7 ng/ml [95% CI 3.1–7.1] in
patients without hydroxychloroquine; P = 0.53).
The correlation between BAFF polymorphism and protein level
led us to investigate whether a similar correlation could be
found with BAFF mRNA level in PBMCs from patients with
pSS. The median BAFF mRNA normalized level was 43.39
(25th to 75th percentile: 17–62.2). Two of the 40 patients had
outlying BAFF/β-actin values of 269 and 183.8. These
patients had no specific clinical features; the reassessment of
BAFF mRNA levels in these patients confirmed these values.
BAFF polymorphism was not associated with BAFF mRNA
level; BAFF mRNA level was not significantly different
between patients carrying -871 T allele and those not carrying
-871 T allele (median normalized BAFF mRNA levels 36.8
[95% CI 29.6–54.1] and 40.5 [95% CI 9.6–269], respec-
tively; P = 0.55; Fig. 3). When the two patients with outlying
values for BAFF mRNA and CC genotype were not taken into
account, a nonsignificant trend was observed toward an asso-
ciation between BAFF polymorphism and BAFF mRNA levels
(median normalized BAFF mRNA level: 43.8 in patients carry-
ing -871 T allele and 30.2 in patients with CC genotype; P =
0.24).
Discussion
The present study is the first to investigate the genetic contri-
bution of BAFF to pSS. Indeed, numerous data support a path-
ogenic role for BAFF in pSS, such as the phenotype of BAFF
transgenic mice [9], which develop Sjögren's syndrome-like
symptoms with age, and the increased serum and salivary
expression of BAFF in patients with pSS [2-6]. Moreover,
because one-third of first-degree relatives of patients with pri-
mary pSS suffer from other autoimmune diseases [10] and
given that BAFF over-expression was also demonstrated in RA
[11] and SLE [12], BAFF could be a good candidate gene in
the predisposition to multiple autoimmune diseases, as was
recently observed for the genes encoding PTPN22, RUNX1,
PDCD1 and CTLA4 [13]. The findings presented here demon-
strate that BAFF gene polymorphism is associated neither
with predisposition to pSS nor with a specific pattern of anti-
body secretion, including anti-SSA/SSB autoantibodies, rheu-
matoid factor, and serum gammaglobulin and IgG levels.
Likewise, the absence of genetic involvement of BAFF in RA
or SLE was reported in Japanese patients [7]. To a greater
extent, no association was observed between polymorphisms
in BCMA [14], TACI [15] and BAFF receptors, and RA or SLE.
This suggests that autoimmunity does not result from a primary
genetically determined activation of the BAFF/BAFF receptor
system, in contrast to the recent demonstration of the genetic
association between common variable immunodeficiency and
TACI [16]. Like in mouse models of autoimmunity, BAFF over-
expression might amplify an independent genetically deter-
mined autoimmune proclivity, rather than creating an autoim-
mune disease de novo [17].
Interestingly, among the 26 individuals (13 patients with pSS
and 13 control individuals) who were entirely sequenced for
the BAFF gene, the only SNP detected at a significant fre-
quency in the present study was located in the promoter
region of BAFF. Moreover, this promoter polymorphism lies in
a putative binding site for nuclear factor-κB, which is known to
enhance BAFF gene expression. To date, the only data availa-
ble regarding the functional role of BAFF polymorphism are
derived from a Japanese study that included 12 healthy indi-
Figure 2
Association between BAFF -871 T/C polymorphism and serum BAFF  level in 95 patients with pSS Association between BAFF -871 T/C polymorphism and serum BAFF 
level in 95 patients with pSS. The bar represents the standard error. 
BAFF = B-cell-activating factor; pSS, primary Sjögren's syndrome.
Figure 1
Association between BAFF -871 T/C polymorphism and serum BAFF  level in 95 patients with pSS Association between BAFF -871 T/C polymorphism and serum BAFF 
level in 95 patients with pSS. Bars represent mean serum BAFF levels. 
BAFF = B-cell-activating factor; pSS, primary Sjögren's syndrome.Arthritis Research & Therapy    Vol 8 No 1    Gottenberg et al.
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viduals [7] and reported a significant association between -
871 T allele and increased BAFF mRNA level in blood mono-
cytes. We therefore investigated the association between
BAFF -871 T/C polymorphism and BAFF expression, and
focused first on the correlation between BAFF polymorphism
and serum level as assessed by enzyme-linked immunosorb-
ent assay. Interestingly, serum BAFF protein level was high in
patients carrying two -871 T alleles, intermediate in patients
with one T allele, and low in patients without a T allele. It is
remarkable to find such an association in a cross-sectional
study because BAFF level could have been modulated by dis-
ease activity and perhaps by treatment. BAFF serum level
remained correlated with T allele even in patients without anti-
SSA/SSB autoantibodies, in whom disease is usually less sys-
temic. Moreover, we previously reported that BAFF level was
not associated with systemic features in pSS [8]. Likewise, no
association was found between BAFF level and disease activ-
ity in SLE patients [12]. Moreover, no significant change in
serum BAFF level was observed in our patients treated with
low-dose corticosteroids or hydroxychloroquine. Accordingly,
in a longitudinal study [12] it was found that the BAFF protein
level was stable in 74% of patients with SLE and that immuno-
suppressive medications (except high-dose corticosteroids,
which was never prescribed to our patients) did not influence
BAFF level.
Surprisingly, no correlation was observed between BAFF pol-
ymorphism and BAFF mRNA levels in patients with pSS. The
absence of concordance between BAFF protein and mRNA
regarding the correlation with BAFF polymorphism might be
related to the fact that assessments of BAFF mRNA and pro-
tein were not performed on the same day. Despite this limita-
tion, our findings suggest that BAFF mRNA does not correlate
with protein level in some patients with pSS. Interestingly, a
longitudinal study evaluating BAFF levels also reported that
the BAFF mRNA phenotype did not match the BAFF protein
phenotype in as many as 42% of patients with SLE, with recip-
rocal changes between mRNA and protein levels in 21% of
patients [12]. In autoimmune diseases there might be some
feedback regulatory mechanism through which the increase in
circulating levels of BAFF protein leads to downregulation of
BAFF transcription. This might contribute to a transient disso-
ciation between BAFF protein and BAFF mRNA levels. Satu-
ration of BAFF receptors and/or a downregulation of their
expression in patients with increased BAFF levels might fur-
ther amplify the increase in BAFF protein levels. More specu-
latively, a decrease in ∆BAFF protein, which inhibits secretion
of BAFF [18], would also increase BAFF protein level without
affecting BAFF mRNA level. The absence of concordance
between BAFF protein and mRNA regarding the correlation
with BAFF polymorphism precludes any definitive conclusion
regarding the functional role of this polymorphism. To provide
direct evidence that -871 T polymorphism of the BAFF pro-
moter gene is associated with production of BAFF protein,
analysis of BAFF expression must be performed using trans-
fectant expressing -871 T in the promoter gene. Likewise, the
functional difference between -871 T and -871 C on transcrip-
tion factor binding should be investigated using luciferase
assay or electrophoretic mobility shift assay.
Conclusion
The association of BAFF polymorphism with BAFF levels
requires further investigation. The increase in BAFF level in
pSS might be under the control of environmental factors. Inter-
estingly, BAFF gene expression was reported to be interferon
inducible in target organs of patients with RA [19] and multiple
sclerosis [20]. Moreover, pathogenic activation of interferon
signalling pathways was recently demonstrated in salivary
glands of patients with pSS [21,22]. Thus, the role played by
interferons in BAFF over-expression in pSS deserves further
investigation. Finally, our study clearly demonstrates that BAFF
gene polymorphism is neither involved in genetic predisposi-
tion to pSS nor associated with a specific pattern of antibody
production.
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